November 22, 2024
2 min watch
Save
VIDEO: ANXV shows early positive results in treatment of retinal vein occlusion
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Anders Haegerstrand, MD, PhD, and Anna Frostegård, MD, PhD, of Annexin Pharmaceuticals discuss a phase 2a trial of ANXV for the treatment of retinal vein occlusion.
“We achieved our main goals for the study,” Frostegård said. “We see that ANXV is well tolerated and safe, and we also see signals of effect, also making it clear that we differentiate ourselves from anti-VEGF.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Frostegård reports being chief scientific and chief medical officer of Annexin Pharmaceuticals. Haegerstrand reports being CEO of Annexin Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.